Compare iShares MSCI China ETF (MCHI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI China ETF trades at $52.53 (market cap $5.94B), while Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 12.8× iShares MSCI China ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MCHI | REGN | |
|---|---|---|
Market Cap | $5.94B | $76.14B |
Volume | 1,575,471 | 500,239 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $852.03 |
52-Week Low | $50.48 | $557.73 |
Typical Hold Time | 63 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $52.46, up 1.59% today, but faces strong bearish technical signals with 13 sell signals on moving averages. The ETF's valuation remains historically cheap compared to US indices, with Seeking Alpha noting the discount despite significant tech exposure. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions ahead of key US-China meetings.
Outlook remains cautious given bearish technicals and China's macroeconomic headwinds, though the valuation discount presents potential opportunity. Key risks include US-China trade tensions and weak domestic consumption. Institutional activity shows mixed signals with recent purchases by Empowered Funds offset by sales from Acima Private Wealth.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
